KMBJN, you should email Leo that comment by some bio president, I'm sure he would get a laugh from it:
He talks to biotech and pharma management quite a bit, and sent me a very brief note the other day that some antibiotic company's president told him "there is significant renal toxicity." I was very surprised and pointed him to links showing no such thing in 250+ patients in the two Phase II studies. So either the other antibiotic company's president is wrong out of ignorance (more likely), willfully spreading misinformation (possible?), or somehow correct (highly doubtful).
KMBJN - thx for sharing the story. I have shared CTIX portfolio and story with my friends. 2 of them invested in it - not much but they looked at this as pure lottery or gambling. Luckily they invested below $2 - so happy with the SP increase. However their point is - why the market is ignoring such a wonderful range of portfolio - is there something wrong? My conviction - market is ignorant. I hope i am correct.
"there is a lot of unawareness about brilacidin and CTIX still, perhaps because it's such a low market cap OTC stock"
It's not a commentary on the science, it's just that most (almost all) mutual fund/institutional investors have hard and fast rules that screen out companies that aren't on an exchange and/or sell for less than $X (X used to be 5, may be more nowadays). Because they are locked into the parameters in their prospectus they can't invest in companies that fall below them no matter how promising, or even profitable, they may be.
Market Data 
Markets 
AI
